NDA Deficiencies Prolonged Review Of Lunesta Sleep Aid – FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Inadequacies in Sepracor's NDA for the insomnia drug Lunesta (eszopiclone) kept FDA from reaching an approval decision during the first review cycle, agency review documents indicate